The FDA approved darolutamide for mHSPC on June 3, [2025], so we now have this in our armamentarium, along with all the other ...

Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster presentation highlighting extended follow up analyses examining ...

The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), which is a menin inhibitor, for the treatment ...

Brekiya® autoinjector, a new specialty therapy from Amneal, is now available for prescription exclusively through Walgreens ...

The FDA approved elinzanetant (Lynkuet), a new type of nonhormonal drug to treat disruptive menopausal hot flashes, Bayer ...

The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia with a ...

About ORLADEYO ® (berotralstat) ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 ...

Brekiya® is now available for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data will be presented at the 2025 American Society of Nephrology Kidney Week, taking place from November 6 to 9 ...

Asahi Kasei, a global provider of healthcare and pharmaceutical solutions, announced that Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules), has been included ...

Results from the pivotal EV-303 trial demonstrated that, when used before and after surgery, the combination reduced the risk of recurrence, progression or death by 60% and the risk of death by 50% in ...

While inhalers and nasal sprays with corticosteroids are often prescribed for asthma and allergies, experts warn that ...